Literature DB >> 18227180

Multilaboratory testing of antifungal combinations against a quality control isolate of Candida krusei.

Vishnu Chaturvedi1, Rama Ramani, Mahmoud A Ghannoum, Scott B Killian, Nicole Holliday, Cindy Knapp, Luis Ostrosky-Zeichner, Shawn A Messer, Michael A Pfaller, Naureen J Iqbal, Beth A Arthington-Skaggs, Jose A Vazquez, Tin Sein, John H Rex, Thomas J Walsh.   

Abstract

Candida krusei ATCC 6258 was tested by eight laboratories using 96-well plates containing checkerboard pairwise combinations of amphotericin B (AMB), posaconazole (PSC), caspofungin (CSP), and voriconazole (VRC). The methodology led to reproducible results across the laboratories. All drug combinations yielded MICs lower than the MICs of any two drugs tested singly, and combinations of AMB, PSC, CSP, and VRC were indifferent (no antagonism) by summations of fractional inhibitory concentration.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18227180      PMCID： PMC2292538          DOI： 10.1128/AAC.00574-07

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  16 in total

Review 1.  Combinations of antifungal agents in therapy--what value are they?

Authors:  Manuel Cuenca-Estrella
Journal:  J Antimicrob Chemother       Date:  2004-09-16       Impact factor: 5.790

2.  Synergistic activities of fluconazole and voriconazole with terbinafine against four Candida species determined by checkerboard, time-kill, and Etest methods.

Authors:  Emilia Cantón; Javier Pemán; Miguel Gobernado; Angel Viudes; Ana Espinel-Ingroff
Journal:  Antimicrob Agents Chemother       Date:  2005-04       Impact factor: 5.191

Review 3.  New agents for the treatment of fungal infections: clinical efficacy and gaps in coverage.

Authors:  Elias K Spanakis; George Aperis; Eleftherios Mylonakis
Journal:  Clin Infect Dis       Date:  2006-09-08       Impact factor: 9.079

4.  Comparison of Etest, chequerboard dilution and time-kill studies for the detection of synergy or antagonism between antifungal agents tested against Candida species.

Authors:  R E Lewis; D J Diekema; S A Messer; M A Pfaller; M E Klepser
Journal:  J Antimicrob Chemother       Date:  2002-02       Impact factor: 5.790

5.  Resistant Microascus cirrosus pneumonia can be treated with a combination of surgery, multiple anti-fungal agents and a growth factor.

Authors:  Celalettin Ustun; Gerwin Huls; Marc Stewart; Kieren A Marr
Journal:  Mycopathologia       Date:  2006-10       Impact factor: 2.574

Review 6.  Clinical efficacy of new antifungal agents.

Authors:  Carol A Kauffman
Journal:  Curr Opin Microbiol       Date:  2006-08-09       Impact factor: 7.934

7.  International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia.

Authors:  L Ostrosky-Zeichner; D Kontoyiannis; J Raffalli; K M Mullane; J Vazquez; E J Anaissie; J Lipton; P Jacobs; J H Jansen van Rensburg; J H Rex; W Lau; D Facklam; D N Buell
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-10       Impact factor: 3.267

Review 8.  Role of antifungal susceptibility testing in patient management.

Authors:  Graeme Forrest
Journal:  Curr Opin Infect Dis       Date:  2006-12       Impact factor: 4.915

9.  Antifungal activities of fluconazole, caspofungin (MK0991), and anidulafungin (LY 303366) alone and in combination against Candida spp. and Crytococcus neoformans via time-kill methods.

Authors:  Ellen E Roling; Michael E Klepser; Ashley Wasson; Russell E Lewis; Erika J Ernst; Michael A Pfaller
Journal:  Diagn Microbiol Infect Dis       Date:  2002-05       Impact factor: 2.803

10.  Combination therapy of disseminated coccidioidomycosis with caspofungin and fluconazole.

Authors:  Dae Won Park; Jang Wook Sohn; Hee Jin Cheong; Woo Joo Kim; Min Ja Kim; Je Hyeong Kim; Chol Shin
Journal:  BMC Infect Dis       Date:  2006-02-15       Impact factor: 3.090
View more
  11 in total

1.  Multilaboratory testing of two-drug combinations of antifungals against Candida albicans, Candida glabrata, and Candida parapsilosis.

Authors:  Vishnu Chaturvedi; Rama Ramani; David Andes; Daniel J Diekema; Michael A Pfaller; Mahmoud A Ghannoum; Cindy Knapp; Shawn R Lockhart; Luis Ostrosky-Zeichner; Thomas J Walsh; Karen Marchillo; Shawn Messer; Amanda R Welshenbaugh; Cara Bastulli; Noreen Iqbal; Victor L Paetznick; Jose Rodriguez; Tin Sein
Journal:  Antimicrob Agents Chemother       Date:  2011-01-31       Impact factor: 5.191

2.  Multilaboratory testing of antifungal drug combinations against Candida species and Aspergillus fumigatus: utility of 100 percent inhibition as the endpoint.

Authors:  Ping Ren; Ming Luo; Shao Lin; Mahmoud A Ghannoum; Nancy Isham; Dan J Diekema; Michael A Pfaller; Shawn Messer; Shawn R Lockhart; Naureen Iqbal; Vishnu Chaturvedi
Journal:  Antimicrob Agents Chemother       Date:  2014-12-15       Impact factor: 5.191

3.  In Vitro Evaluation of Antifungal Drug Combinations against Multidrug-Resistant Candida auris Isolates from New York Outbreak.

Authors:  Brittany O'Brien; Sudha Chaturvedi; Vishnu Chaturvedi
Journal:  Antimicrob Agents Chemother       Date:  2020-03-24       Impact factor: 5.191

4.  Broth microdilution and time-kill testing of Caspofungin, voriconazole, amphotericin B and their combinations against clinical isolates of Candida krusei.

Authors:  Yasemin Oz; Ilknur Dag; Nuri Kiraz
Journal:  Mycopathologia       Date:  2011-08-13       Impact factor: 2.574

5.  Chronic rhinofacial mucormycosis caused by Mucor irregularis (Rhizomucor variabilis) in India.

Authors:  B M Hemashettar; R N Patil; Kerry O'Donnell; Vishnu Chaturvedi; Ping Ren; Arvind A Padhye
Journal:  J Clin Microbiol       Date:  2011-04-20       Impact factor: 5.948

6.  Evaluating the resistance to posaconazole by E-test and CLSI broth microdilution methodologies of Candida spp. and pathogenic moulds.

Authors:  R Araujo; S Costa-de-Oliveira; I Coutinho; A G Rodrigues; C Pina-Vaz
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-04-07       Impact factor: 3.267

7.  Rhizomucor variabilis var. regularior and Hormographiella aspergillata infections in a leukemic bone marrow transplant recipient with refractory neutropenia.

Authors:  Mayssa M Abuali; Roberto Posada; Gustavo Del Toro; Elizabeth Roman; Rama Ramani; Sudha Chaturvedi; Vishnu Chaturvedi; Vincent J LaBombardi
Journal:  J Clin Microbiol       Date:  2009-10-21       Impact factor: 5.948

8.  Activity of MGCD290, a Hos2 histone deacetylase inhibitor, in combination with azole antifungals against opportunistic fungal pathogens.

Authors:  M A Pfaller; S A Messer; N Georgopapadakou; L A Martell; J M Besterman; D J Diekema
Journal:  J Clin Microbiol       Date:  2009-09-30       Impact factor: 5.948

9.  Multicenter Collaborative Study of the Interaction of Antifungal Combinations against Candida Spp. by Loewe Additivity and Bliss Independence-Based Response Surface Analysis.

Authors:  Joseph Meletiadis; David R Andes; Shawn R Lockhart; Mahmoud A Ghannoum; Cindy C Knapp; Luis Ostrosky-Zeichner; Michael A Pfaller; Vishnu Chaturvedi; Thomas J Walsh
Journal:  J Fungi (Basel)       Date:  2022-09-16

10.  In vitro studies of the antibacterial activity of Copaifera spp. oleoresins, sodium hypochlorite, and peracetic acid against clinical and environmental isolates recovered from a hemodialysis unit.

Authors:  Rosimara Gonçalves Leite Vieira; Thaís da Silva Moraes; Larissa de Oliveira Silva; Thamires Chiquini Bianchi; Rodrigo Cassio Sola Veneziani; Sérgio Ricardo Ambrósio; Jairo Kenupp Bastos; Regina Helena Pires; Carlos Henrique Gomes Martins
Journal:  Antimicrob Resist Infect Control       Date:  2018-01-24       Impact factor: 4.887
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.